跳至主要内容
临床试验/NCT04426643
NCT04426643已完成1 期

Treatment of Urinary Incontinence in Men After Prostatectomy With Autologous Adipose-derived Mesenchymal Stem Cells Mixed With Collagen Gel and Injected Submucousely

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2020年8月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
10
试验地点
2
主要终点
Number of cured patients

研究概览

简要总结

Treatment of patients with urinary incontinence after prostatectomy using injection of autologous adipose-derived mesenchymal stem cells mixed with collagen gel

详细描述

During the implementation of the project, it is planned to develop a method for the treatment of men urinary incontinence caused by prostatectomy using injection of autologous adipose-derived mesenchymal stem cells mixed with collagen. The positive outlook for the effectiveness of MSCs is due to the following:

  • the ability of MSCs to stimulate tissue regeneration
  • positive results of preclinical studies of the method of treatment of urinary incontinence in animals.

In study planing to include 5 patients. MSCs will be isolated from adipose tissue, cultured and then transplanted back to the periurethral area by five point injection in rhabdosphincter and submucosal space of urethra using the cystourethroscope. For injection in submucosal space MSCs (20*10^6 cells) will be mixed with collagen solution (3,5% w|w). Follow up patients monitoring will occur at 1,3,6 and 12 months after injection.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Urinary incontinence
  • absence of acute inflammatory manifestations in the genitourinary system
  • period after prostatectomy is at least 12 months

排除标准

  • urethral or bladder malformations
  • acute and chronic infectious diseases: HIV, viral hepatitis, tuberculosis
  • mental disorders

结局指标

主要结局

Number of cured patients

时间窗: 3 months

Number of patients cured

Number of patients with treatment-related adverse events

时间窗: 4 weeks

MSC application related adverse events assessed by blood count, liver and function tests

次要结局

未报告次要终点

研究者

研究点 (2)

Loading locations...

相似试验